Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics: Introduction (00:00) Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44) Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00) Utility of Belantamab Mafodotin in R/R MM (49:29) Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01) CME information and select publications

For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress

Research To Practice | Oncology Videos

[SPEAKER_A] Well, hello, good afternoon, and welcome to Recent Advances in Cancer Care: New Paradigms, Novel Agents, and What It Means for the Oncology Nurse for Patients with Relapsed and Refractory Multiple Myeloma. So I'm Natalie S Callander from the University of Wisconsin. And just let me say what a delight it is to be here in San Antonio. I lived here for 13 years. I was stationed in the Air Force. I worked at Wolford Hall Medical Center when it still existed, UTHSCSA. And so it's just a delight. And go Spurs. So now I would like to introduce the rest of our faculty here. We have Beth Faiman from the University of Cleveland, excuse me. Then we have Mary Steinbach from the University of Utah Huntsman Cancer Center. And finally, Hans Lee from Nashville, the Sarah Cannon Cancer Center. These are our disclosures. We'll just go through for all of our discussants. And we'd like to thank our support here today. This is an educational activity. We are going to talk about non-FDA-approved of agents. Now, what we're gonna try to do here is break down some of the newer agents for relapsed and refractory myeloma. And in particular, we'll talk about just some of the graphs that show us how patients are doing in terms of survival. But we really want to be able to tell you the key take-home messages of how is this important to patients. So let's get started. So this is, we're gonna do a general discussion talking about what happens when people have relapsed myeloma. And then we're gonna talk about CAR-T, complications of CAR-T. We're gonna talk about bispecific antibodies and those complications. And then we're gonna talk about belantamab that may be an unfamiliar compound for you.

For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress

Read the full transcript

The candid version is on a podcast,
not the earnings call.

For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.